Quick Answer
Roivant Sciences Ltd. reported Net Income Loss of -$171.98 million for the year ending 2025.
- Roivant Sciences Ltd. showed a decrease of -104.0% in Net Income Loss from 2024 to 2025.
- This data is from Roivant Sciences Ltd.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$3.24 million | Q3 2020: -$35.40 million | Q4 2020: -$261.03 million | Q2 2021: -$82.18 million | Q3 2021: -$208.48 million | Q4 2021: -$284.54 million | Q2 2022: -$331.81 million | Q3 2022: -$291.59 million | Q4 2022: -$352.01 million | Q2 2023: -$291.82 million | Q3 2023: -$304.33 million | Q4 2023: $5.10 billion | Q2 2024: $95.30 million | Q3 2024: -$230.18 million | Q4 2024: $169.38 million | Q2 2025: -$223.36 million | Q3 2025: -$113.52 million | Q4 2025: -$265.89 million.
- Over the full 5 years of available data (2021 to 2025), Roivant Sciences Ltd.'s Net Income Loss has grown by 78.7%.
- Historical annual values: Fiscal year 2025: -$171.98 million | Fiscal year 2024: $4.35 billion | Fiscal year 2023: -$1.01 billion | Fiscal year 2022: -$845.26 million | Fiscal year 2021: -$809.23 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: